IMMY nur die Besten tickern jung

buran und MfG  

at Two Upcoming Investor Conferences12:05 04.03.14


PR Newswire

SAN DIEGO, March 4, 2014

SAN DIEGO, March 4, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.

On Monday, March 10, 2014, Mr. Baum is scheduled to present at the 26th Annual ROTH Conference at 5:30 pm PT at the Ritz-Carlton Laguna Niguel, California and will be available for one-on-one meetings for conference attendees through the conference request process. The presentation will also be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.imprimispharma.com.  

Later that week on Wednesday, March 12, 2014, Mr. Baum is scheduled to participate at the Northland Capital Markets 2014 Growth Conference at the Omni Berkshire Place Hotel located at 21 East 52nd Street New York, NY,  and will be available for one one-on-one meetings for conference attendees.  Any other meeting requests outside of these two appearances can be directed to the Imprimis IR Team at ir@imprimispharma.com.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Certain of Imprimis' patent-pending technologies and formulations are available today and are being prescribed by physicians.  For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; Imprimis' ability to close the acquisition of Pharmacy Creations, LLC and realize the expected benefits of the transaction; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT:  Jen Carroll

jcarroll@imprimispharma.com

858.704.4587

SOURCE Imprimis Pharmaceuticals, Inc.


Quelle: PR Newswire
 

:::::::::::::::::::7,87 $ +1,29% +0,10 $

In Euro: 5,6789 € | Nasdaq, 13.03.14::::::: buran und MfG und danke und weitermachen  

Zeit  Kurs  Stück  
20:59:42 7,90 $  100  
20:59:10 7,90 $  100  
20:58:54 7,90 $  100  
20:58:50 7,89 $  100  
20:56:11 7,90 $   400  
20:53:19 7,90 $  1.300  
20:53:19 7,89 $  100  
20:53:19 7,889 $  800  
20:51:30 7,851 $  100  
20:51:30 7,85 $  200  
20:51:30 7,86 $  200  
20:48:47 7,861 $  100  
20:45:50 7,90 $  100  
20:45:35 7,89 $  100  
20:44:36 7,88 $  500  
20:44:36 7,89 $  100  
20:41:19 7,90 $  100  
20:37:26 7,86 $  100  
20:37:11 7,86 $  300  
20:36:54 7,85 $  500  
20:36:48 7,85 $  500  
20:36:37 7,85 $  1.000  
20:36:34 7,86 $  600  
20:35:28 7,85 $  1.300  
20:35:03 7,84 $  800  
20:35:03 7,841 $  200  
20:32:14 7,849 $  700  
20:32:13 7,85 $  1.300  
20:30:25 7,85 $  700  
20:30:15 7,85 $  300  
20:10:42 7,83 $  100  
20:06:49 7,83 $  100  
20:05:53 7,83 $  300  
19:53:44 7,80 $  100  
18:52:51 7,80 $  1.000  
18:51:10 7,79 $  100  
18:33:44 7,7999 $  500  
18:10:01 7,75 $  500  
18:09:55 7,75 $  500  
18:09:51 7,75 $  500  
17:52:11 7,75 $  600  
17:41:48 7,75 $  100  
17:41:47 7,75 $  900  
17:37:45 7,75 $  1.000  
17:37:41 7,75 $  1.300  
17:37:39 7,75 $  2.500  
17:37:39 7,76 $  200  
17:27:03 7,76 $  100  
16:56:40 7,73 $  200  
16:53:30 7,6891 $  1.000  
16:16:09 7,76 $   200  
16:16:08 7,7699 $  2.200  
16:16:08 7,77 $  100  
16:12:28 7,75 $  400  
16:06:37 7,75 $  100  
16:05:40 7,75 $  100  
15:14:32 7,75 $  1.000  
15:03:54 7,77 $  700  
15:03:54 7,681 $  100  
15:03:54 7,77 $  300  
15:03:54 7,76 $  200  
15:02:49 7,763 $  500  

GrB  

::::::::::::::::::: 7,90 $ +0,38% +0,03 $

In Euro: 5,6787 € | Nasdaq, 14.03.14::::::: von Sante Nirgendwo  

Zeit  Kurs  Stück  
15:35:41 7,9799 $  125
_________________
GRATULATION  

Preis pro share 7,95 $ Schleife 200 spread 1,92% buran und MfG und trullala und trallala  

Bucheinsicht http://www.ariva.de/...icals,_inc.-aktie/times_and_sales?boerse_id=40 GrB  

Bucheinsicht
http://www.ariva.de/...icals,_inc.-aktie/times_and_sales?boerse_id=40

buran und MfG und Thx und weitermachen und SCHICK  

:::::::::::::::::::::::: 7,97 $ +3,24% +0,25 $

In Euro: 5,7225 € | Nasdaq, 18.03.14:::::: und nich schummeln beim TICKER FUMMELN  

Börsenbuch http://www.ariva.de/...icals,_inc.-aktie/times_and_sales?boerse_id=40 GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
19.03.14 6,9201 7,9799 6,9201  7,42 $ 24.155 158 T

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
20.03.14 7,5499 7,5499 7,20  7,21 $ 28.469 207 T

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
21.03.14 7,288 7,52 6,94  6,95 $ 34.714 248 T

GrB  

13th Annual Needham Healthcare Conference
11:05 25.03.14

PR Newswire

SAN DIEGO, March 25, 2014

SAN DIEGO, March 25, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.

Mr. Baum will be available for one-on-one meetings for conference attendees through the conference request process. Any other meeting requests outside of this event can be directed to the Imprimis IR Team at ir@imprimispharma.com. The April 9th presentation will be webcast and can be accessed on the "Events" page of the Company's website at www.imprimispharma.com.  

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Certain of Imprimis' patent-pending technologies and formulations are available today and are being prescribed by physicians.  For more information, please visit  or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; Imprimis' ability to close the acquisition of Pharmacy Creations, LLC and realize the expected benefits of the transaction; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT:  Jen Carroll

jcarroll@imprimispharma.com

858.704.4587

SOURCE Imprimis Pharmaceuticals, Inc.


Quelle: PR Newswire  

novel, and customizable medicines to physicians and patients at accessible prices. One of our key strategies to execute our business model is the use of compounding pharmacies to formulate and distribute to physicians and patients our proprietary compounded drug formulations and technologies. Through the initiation of customer relationships with our family of offerings, we hope to serve our customers’ needs and in turn grow our business.

Our hope is that through the success of our business, we will reduce healthcare costs and provide Americans access to high quality, novel and previously unavailable medicines.

Thank you for your interest in Imprimis Pharmaceuticals.

Mark L. Baum
Chief Executive Officerhttp://imprimispharma.com/  

healthcare economy and solve unmet patient needs through the development and commercialization of proprietary sterile and topical drug formulations.http://imprimispharma.com/
 

and customizable medicines to physicians and patients at accessible prices. Working with leading inventor physicians and pharmacists, we evaluate intellectual property related to innovative compounded drug formulations in several areas, conduct a market-related review of a formulation, and validate the clinical experience of a development candidate outside of the inventor’s medical or pharmacy practice.  For development opportunities that pass our proprietary review methodology, we engage in development and commercialization activities in order to advance the expansion and ultimate commercial success of our growing proprietary compounded drug formulations portfolio.  We now own formulations in ophthalmology, wound management and urology that we believe may offer unique advantages over commercially available formulations, and are actively pursuing additional development opportunities.http://imprimispharma.investorroom.com/
 

http://imprimispharma.investorroom.com/index.php?s=43 GrB  

Imprimis Pharmaceuticals, Inc.
12626 High Bluff Drive, Suite 150
San Diego, CA 92130
Phone: 858-704-4040
Fax: 858-345-1745
@Kosmonova buran,ISS Orbit
http://imprimispharma.com/contact/  

Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Presented in Two Sessions at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Cong
14:05 22.04.14

PR Newswire

SAN DIEGO, April 22, 2014

SAN DIEGO, April 22, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today its attendance and physicians' presentations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress in Boston from April 25-29, 2014.  

The American Society of Cataract and Refractive Surgery is an international educational society with more than 9,000 members. Its mission is to advance the art and science of ophthalmic surgery and the knowledge and skills of ophthalmic surgeons by providing clinical and practice management education and by working with patients, government, and the medical community to promote the delivery and advancement of high-quality eye care.

Details of the presentations of physician and patient experience with Imprimis' patent-pending compounded formulations at ASCRS include:

Sunday, April 27, 2014, 1:00-2:30 p.m. EDT, "IVTA & Antibiotics," Jeffrey T. Liegner, Course 27-303: Better Surgery Through Chemicals: Topical and Intracameral Agents for the Anterior Segment Surgeon, Room 253B.
Sunday, April 27, 2014, 3:33 p.m. EDT, "Intravitreal Placement of Antibiotic/Steroid as Substitute for Postoperative Drops After Cataract Surgery," M. Stewart Galloway, MD, Session: Intraocular Surgery - Medications, Room 152.
Additional information about Imprimis and the presentations will be available to conference attendees who visit the Imprimis booth (#1481).

Imprimis' proprietary patent-pending ophthalmic compounded formulations are now available with a physician's prescription in many states while the Company continues its Go Dropless™ campaign (http://GoDropless.com/). The campaign was created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.

ABOUT DROPLESS OPHTHALMIC SURGERY FORMULATIONS

Imprimis acquired the intellectual property for these patent-pending formulations in August of 2013. As the Company stated at that time, the current treatment regimen for the prevention of post-cataract surgery complications is a costly pre-operative and post-operative patient-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack a supportive caregiver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues. Imprimis' unique drug formulations utilize a fourth generation quinolone therapy combined with anti-inflammatory agent, providing new choices for physicians to address the primary ocular complications of ophthalmic surgery - risk of infection and post-operative inflammation.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices. Imprimis is pioneering a new commercial pathway using compounding pharmacies for the formulation and distribution of its proprietary drug therapies which include formulations in ophthalmology, wound management and urology.  For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT:  Jen Carroll

jcarroll@imprimispharma.com

858.704.4587

SOURCE Imprimis Pharmaceuticals, Inc.


Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  09.05.14     6,831     6,831§6,755 6,79 $ 6.720 44.769

buran und MfG and FULL MÄDDÄLL DSCHÄGGÄDD
 

http://www.ariva.de/news/...ations-at-2014-Kiawah-Eye-Meeting-5053483 GrB  

http://www.ariva.de/news/...yed-Would-Prefer-Dropless-Therapy-5079762 GrB  

Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium
14:05 24.07.14

PR Newswire

SAN DIEGO, July 24, 2014

SAN DIEGO, July 24, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations,  announced today that two Key Opinion Leader (KOL) presentations that describe the benefits of dropless cataract surgery formulations will be delivered at the upcoming American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Valley, Utah from July 24 – 27, 2014.  

The American-European Congress of Ophthalmic Surgery is a unique collaboration of physicians, ophthalmic industry executives, select venture capitalists and technology entrepreneurs. The Society meets three times each year - in the US and Europe - to evaluate new developments in technology, surgical technique, clinical studies and progressive patient care. Its mission is to advance vision care and improve patients' quality of life through Innovation, Education and Advocacy.

Imprimis continues its Go Dropless™ campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations the company has developed in conjunction with physicians and pharmacists. Details of the AECOS presentations include:

Friday, July 25, 2014 – 9:20 a.m. – 9:30 a.m. MDT "Branded vs. Generic Options: What's Happening with Drop Prices? How Does It Impact the Premium Practice/Procedure?," Dr. Carlos Buznego
Sunday, July 27, 2014 - 7:08 a.m. – 7:16 a.m. MDT "Use of Intraocular Meds During Cataract Surgery with the Goal of Reducing or Eliminating Post-Op Drops," Dr. William Trattler
Imprimis' proprietary patent-pending ophthalmic compounded formulations are now available with a physician's prescription in 32 states and territories while the Company continues its Go Dropless™ campaign (http://GoDropless.com/). Currently two compounded antibiotic and steroid formulations are available in single, injectable, intraocular doses administered during cataract surgery. The preservative-free formulations generally contain 15 mg triamcinolone plus 1 mg moxifloxacin per ml and can also include vancomycin and the relative strengths of the active ingredients can be tailored to individual patients.  Advantages include reduction of compliance concerns, reduction of staff and chair time spent on instructions and follow-up with post-operative surgical patients, as well as calls from pharmacists. Two recent studies both found the use of these formulations to be positive in overall patient compliance, cost, and general experience.1-2

Furthermore, the company recently shared results of a survey of leading national cataract surgeons that showed 20 out of the 21 physicians surveyed expressed favorable opinions to the concept of Imprimis' single intraocular injection administered at the conclusion of cataract surgery.  These surgeons' perspectives examine the benefits of dropless cataract surgery for both doctors and patients. Specifically, the surgeons highlighted attributes related to convenience and compliance. To watch the complete video interviews, interested parties can go to www.GoDropless.com/why-go-dropless.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices. Imprimis is pioneering a new commercial pathway using compounding pharmacies for the formulation and distribution of its proprietary drug therapies which include formulations in ophthalmology, wound management and urology. For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; including its ability to maintain compliance with applicable state and federal laws and regulations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

1 Liegner J. Better surgery through chemicals. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.

2 Galloway MS. Intravitreal placement of antibiotic/steroid as a substitute for post-operative drops following cataract surgery. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.

MEDIA CONTACT:  Jen Carroll

jcarroll@imprimispharma.com

858.704.4587

SOURCE Imprimis Pharmaceuticals


Quelle: PR Newswire